|
T1564 |
Cisplatin
|
cis-Diaminodichloroplatinum,CDDP |
DNA Alkylator/Crosslinker
,
Ferroptosis
,
DNA/RNA Synthesis
,
Autophagy
|
|
Cisplatin (CDDP) is a DNA cross-linking agent. Cisplatin has antitumor activity and inhibits DNA synthesis by forming DNA adducts in cancer cells. Cisplatin also activates iron death and induces autophagy. |
|
T82715 |
Cisplatin-resistant cells-IN-1
|
|
|
|
Cisplatin-resistant cells-IN-1 (Compound 8) exhibits high cytotoxicity against Cisplatin-resistant cells and effectively diminishes metabolic activity at low nanomolar concentrations, with an IC50 ranging from 0.14 to 1.... |
|
T10777 |
CG347B
|
|
HDAC
|
|
CG347B is a selective inhibitor of HDAC6. |
|
T6612 |
NU6027
|
|
ATM/ATR
,
DNA-PK
,
CDK
|
|
NU6027 is a potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors. |
|
T68105 |
Monohydroxycisplatin
|
|
|
|
monohydroxycisplatin is a useful organic compound for research related to life sciences. The catalog number is T68105 and the CAS number is 101311-26-6. |
|
T36404L |
PRLX-93936 HCL
|
PRLX-93936 hcl(903499-49-0 Free base) |
Ferroptosis
,
Reactive Oxygen Species
|
|
PRLX-93936 HCL is an analog of erastin and demonstrated synergistic effects against non-small cell lung cancer (NSCLC) cells with cisplatin. |
|
T35300 |
Zeniplatin
|
Zeniplatinum |
Others
|
|
Zeniplatin (Zeniplatinum) is a new cisplatin complex with anticancer activity for the treatment of metastatic melanoma and kidney cancer. |
|
T1058 |
Carboplatin
|
NSC 241240,CBDCA,JM-8 |
DNA Alkylator/Crosslinker
,
DNA/RNA Synthesis
,
Autophagy
|
|
Carboplatin (JM-8) is a cisplatin derivative, a DNA synthesis inhibitor. Carboplatin binds to DNA, inhibits replication and transcription, and induces cell death. Carboplatin has antitumor activity. |
|
T1478 |
Ondansetron hydrochloride dihydrate
|
SN 307,NSC 665799,GR 38032,Ondansetron hydrochloride |
5-HT Receptor
|
|
Ondansetron hydrochloride dihydrate (GR 38032) is a competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, a... |
|
T60904 |
ERCC1-XPF-IN-2
|
|
Others
|
|
ERCC1-XPF-IN-2 is active in nucleotide excision repair, cisplatin enhancement and γH2AX assays. ERCC1-XPF-IN-2 is a potent inhibitor of ERCC1-XPF endonuclease with an IC 50 value of 0.6 μM [1]. |
|
T6381 |
Amifostine trihydrate
|
Ethyol trihydrate,WR2721,Amifostine |
Others
,
HIF/HIF Prolyl-Hydroxylase
|
|
Amifostine trihydrate (WR2721) is the first approved radioprotective drug, used to decrease the risk of kidney problems caused by treatment with cisplatin. |
|
T4434 |
Tirapazamine
|
Tirazone,Win59075,SR4233,SR259075 |
Others
|
|
Tirapazamine (Win59075) is a potent cytotoxic agent under hypoxic conditions, can induce apoptosis by inducing breaks in single and double-stranded DNA, as well as chromosomal breaks. The compound sensitizes cells to oth... |
|
T69596 |
SK-575
|
|
|
|
SK-575 is a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. SK-575 potently inhibits the growth of cancer cells bearing BRCA1/2 mutations and induces potent and specifi... |
|
T14919 |
CDKI-73
|
|
Apoptosis
,
CDK
|
|
CDKI-73 is a potent CDK9 inhibitor (Ki: 4 nM). It shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM).The inhibition of CDK9 induces apoptosis and potentiates the effe... |
|
T2410 |
Nedaplatin
|
NSC 375101D |
DNA/RNA Synthesis
|
|
Nedaplatin (NSC-375101D) is a derivative of cisplatin and DNA damage agent for tumor colony forming units (IC50: 94 μM). Containing a novel ring structure in which glycolate is bound to the platinum by a bidentate ligand... |
|
T8845 |
UTL-5g
|
3-Isoxazolecarboxamide, N-(2,4-dichlorophenyl)-5-methyl-,GBL-5g |
TNF
|
|
UTL-5g (3-Isoxazolecarboxamide, N-(2,4-dichlorophenyl)-5-methyl-) is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hemat... |
|
T10936 |
D-I03
|
DI03 |
DNA/RNA Synthesis
|
|
D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 µM. D-I03 specifically inhibits RAD52-dependent single-chain annealing (SSA) and D-loop formation, with IC50 of 5 µM and 8 µM, respectively. D-I03 inhibited the grow... |
|
T7545 |
6-Aminonicotinamide
|
|
Others
|
|
6-Aminonicotinamide (6-AN) is a well-established inhibitor of the NADP+-dependent enzyme. |
|
T16328 |
Nitroaspirin
|
NCX 4016 |
Apoptosis
,
COX
|
|
Nitroaspirin (NCX 4016) is a nitric oxide donor and a nitro-derivative of Aspirin, which combines with Nitroaspirin to inhibit cyclooxygenase. Nitroaspirin induces significant induction of cell cycle arrest and apoptosis... |
|
T6924 |
Riviciclib hydrochloride
|
P276-00 |
Apoptosis
,
CDK
|
|
Riviciclib hydrochloride (P276-00) is a novel CDK1, CDK4 and CDK9 inhibitor with IC50 of 79 nM, 63 nM and 20 nM, respectively. Phase 2/3. |
|
T75268 |
84-B10
|
|
|
|
84-B10, a derivative of 3-phenylglutaric acid, inhibits cisplatin-induced tubular ferroptosis, attenuates mitochondrial damage and oxidative stress, and ameliorates acute kidney injury (AKI) resulting from cisplatin admi... |
|
T68804 |
LC28
|
|
|
|
LC28 is a novel inhibitor of STAT3 signaling, suppressing survival of cisplatin-resistant ovarian cancer cells. |
|
T71655 |
KX1-141
|
|
|
|
KX1-141 is an Src-protein tyrosine kinase inhibitor, which may reduce cisplatin ototoxicity while preserving its antitumor effect. |
|
T24879 |
Thioxodihydroquinazolinone-19
|
Thioxodihydroquinazolinone19 |
|
|
In platinum-resistant A2780cis human ovarian cancer cells, thioxodihydroquinazolinone-19 is an inducer of apoptotic cell death. It acts by exhibiting a strong inhibitory effect in ovarian CSC-LCs in combination with cisp... |
|
T78217 |
(R)-Azasetron besylate
|
SENS-401 |
Phosphatase
|
|
(R)-Azasetron besylate (SENS-401), an orally active calcineurin inhibitor, has been shown to mitigate cisplatin-induced hearing loss and cochlear damage [1][2]. |
|
T39594 |
AKR1B10-IN-1
|
AKR1B10-IN-1 |
|
|
AKR1B10-IN-1, a powerful AKR1B10 (Aldo-Keto Reductase 1B10) inhibitor, demonstrates an IC50 value of 3.5 nM. This compound effectively curtails the proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cance... |
|
T28398 |
Phenanthriplatin
|
cis-[Pt(NH3)2-(phenanthridine)Cl]NO3 |
|
|
Phenanthriplatin, also known as cis-[Pt(NH3)2-(phenanthridine)Cl]NO3, is a new drug candidate. It belongs to a family of platinum(II)-based agents which includes cisplatin, oxaliplatin and carboplatin. Phenanthriplatin A... |
|
T32189 |
Iproplatin
|
JM-9,CHIP,Code name: JM9,JM 9 |
|
|
Iproplatin is a synthetic second-generation platinum-containing compound related to cisplatin. Iproplatin binds to and forms DNA crosslinks and platinum-DNA adducts, resulting in DNA replication failure and cell death. A... |
|
T12737 |
Riviciclib
|
P276-00 (free base) |
Others
|
|
Riviciclib is a potent inhibitor of cyclin-dependent kinase (CDK)(CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively),with antitumor activity on cisplatin-resistant cells. |
|
T32404 |
KMH-233
|
KMH233 |
|
|
KMH-233 is a potent selective LAT1 inhibitor 1 that inhibits the uptake of LAT1 substrate, L-leucine, and cell growth. Even at low concentrations (25 μM), it significantly enhanced the efficacy of betastatin and cisplati... |
|
T65440 |
Sodium Thiosulfate Pentahydrate
|
|
|
|
Sodium thiosulfate (Pentahydrate) is an antioxidant and antifungal. Sodium thiosulfate protects against cisplatin-induced hearing loss in children and is not associated with serious adverse events attributed to its use[3... |
|
T81267 |
RIPK3-IN-4
|
|
RIP kinase
|
|
RIPK3-IN-4 (Compound 42) is a RIPK3 inhibitor that mitigates necroptosis, inflammatory responses, and HK-2 cell damage. It alleviates acute kidney injury by attenuating Cisplatin- and I/R-induced kidney damage, along wit... |
|
T21307 |
Heptaplatin
|
NSC644591 NSCD644591 SKI2053R,Heptaplatin Sunpla,HTP |
|
|
Heptaplatin, a new platinum derivative with anticancer activity, is used against various cancer cell lines, including cisplatin-resistant cancer cell lines. It has been reported to have a response rate of 17% as a single... |
|
T71401 |
Oxaliplatin-d10
|
|
|
|
Oxaliplatin-d10 is intended for use as an internal standard for the quantification of oxaliplatin by GC- or LC-MS. Oxaliplatin is a platinum-containing DNA-crosslinking agent. It induces the formation of DNA inter- and i... |
|
T78841 |
Nrf2-IN-3
|
|
|
|
Nrf2-IN-3 (Compound R16), a Nrf2 inhibitor, binds to KEAP1 mutants (G333C mKEAP1) thereby restoring the impaired KEAP1/NRF2 interactions. This restoration sensitizes KEAP1-mutant cancer cells to chemotherapeutic agents, ... |
|
T71099 |
LLL12
|
|
|
|
LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin and Paclitaxel on ovarian cancer cell formation, migration, and growth [1] . |
|
T81962 |
Lactate transportor 1
|
|
Monocarboxylate transporter
|
|
Lactate Transporter 1 (Compound 1) serves as an active lactate transporter within living cells and exerts cytotoxic effects, exhibiting IC50 values of 3.36 μM in HeLa, 3.27 μM in CAL27, 5.58 μM in MCF7, and 7.66 μM in MC... |
|
T74501 |
NHEJ inhibitor-1
|
|
|
|
NHEJ Inhibitor-1 (Compound C2), a trifunctional Pt(II) complex, mitigates non-homologous end joining (NHEJ)/homologous recombination (HR)-related double strand break (DSB) repairs, combating Cisplatin resistance in non-s... |
|
T73550 |
CUR5g
|
|
|
|
CUR5g, a potent autophagy inhibitor, selectively prevents autophagosome degradation in cancer cells by hindering the fusion of autophagosomes with lysosomes. It disrupts the recruitment of STX17 to autophagosomes through... |
|
T74680 |
NecroIr1
|
|
|
|
NecroIr1, an iridium(III) complex, acts as a necroptosis inducer in Cisplatin-resistant lung cancer cells (A549R). It selectively targets mitochondria, causing oxidative stress and reducing mitochondrial membrane potenti... |
|
T68708 |
Denibulin HCl
|
|
|
|
Denibulin (MN-029) is a novel vascular-disrupting agent that reversibly inhibits microtubule assembly, resulting in disruption of the cytoskeleton of tumor vascular endothelial cells. The results of preclinical study dem... |
|
T71559 |
Melanotan II acetate
|
|
|
|
Melanotan II acetate is an agonist of melanocortin receptor 1 (MC1R), MC3R, MC4R, and MC5R. It has been shown to improve recovery of sciatic nerve function after mechanical injury and increase cisplatin-induced decreases... |
|
T74681 |
NecroIr2
|
|
|
|
NecroIr2, an iridium(III) complex, functions as a necroptosis inducer in cisplatin-resistant lung cancer cells (A549R). It preferentially accumulates in mitochondria, causing oxidative stress and a reduction in mitochond... |
|
T74225 |
ROS-ERS inducer 1
|
|
|
|
ROS-ERS inducer 1, a type II immunogenic cell death (ICD) inducer, is a Pt(II)-N-heterocyclic carbene (Pt(II)-NHC) complex derived from 4,5-diarylimidazole. It induces endoplasmic reticulum stress (ERS) along with reacti... |
|
T36385 |
Ansatrienin A
|
|
|
|
Ansatrienin A is an ansamycin antibiotic and antifungal agent first isolated from S. collinus and S. rishiriensis. In fetal rat long bones, it is an inhibitor of parathyroid hormone-induced calcium release (IC50 = 64 nM)... |
|
T62298 |
PHD2/HDACs-IN-1
|
|
|
|
PHD2/HDACs-IN-1 is a potent mixed inhibitor of PHD2/HDACs, acting on PHD2 (IC50: 1.15 μM), HDAC1 (IC50: 19.75 μM), HDAC2 (IC50: 26.60 μM), HDAC16 (IC50: 15.98 μM). HDACs-IN-1 is a low toxicity nephroprotective agent that... |
|
TP1551 |
Difopein TFA (396834-58-5 free base)
|
Difopein TFA |
|
|
Difopein (TFA), a specific and competitive inhibitor of 14-3-3 protein (a highly conserved eukaryotic regulatory molecule), blocking the ability of 14-3-3 to bind to target proteins and inhibits 14-3-3/Ligand interaction... |
|
T62730 |
TDRL-X80
|
|
|
|
TDRL-X80 is a potent inhibitor of the pigmented dry skin protein (XPA). TDRL-X80 inhibits the DNA binding activity of XPA. TDRL-X80 acts on single, double and cisplatin damaged DNA with IC50 values of 18, 20 and 29 μM in... |
|
T71549 |
RKS-262
|
|
|
|
RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line as... |
|
T71385 |
Aroplatin
|
|
|
|
Aroplatin is a synthetic liposomal formulation of bis-neodecanoate diaminocyclohexane platinum (NDDP), a third-generation platinum complex analogue of cisplatin, with potential antineoplastic activity. After displacement... |
